Clinical observation of Reteplase and Urokinase in treatment of acute ST-segment elevation myocardial infarction

Objective: To compare the therapeutic effect and safety of Reteplase and Urokinase in the thrombolytic therapy for the treatment of acute ST-segment elevation myocardial infarction patients.Methods: 88 cases of acute ST-segment elevation myocardial infarction were divided into Reteplase group(46 cases) and Urokinase group(42 cases).2 hours revascularization rate,4 weeks internal bleeding rate,death rate and cardiovascular complications rate of the two groups were observed and analyzed.Results: The 2 hours revascularization rate of the Reteplase group and the Urokinase group was 86.96% and 73.8% respectively,the difference was statistically significant(P0.05).4 weeks internal bleeding rate and death rate of the Reteplase group were lower than the Urokinase group(8.69%,4.35% vs 14.29%,7.14%),the differences were statistically significant(P0.05).Conclusion: The therapeutic effect and safety of Reteplase in the treatment of ST-segment elevation myocardial infarction is better than Urokinase.